Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Feb;27(1):41–55. doi: 10.1089/cbr.2011.1097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2012, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 7. — Relative anti-neoplastic potency of covalent epirubicin-(C₃-amide)-[anti-HER2/neu] immunochemotherapeutic synthesized utilizing a UV-photoactivated epirubicin-(C₃-amide) intermediate compared to anti-HER2/neu monoclonal immunoglobulin against chemotherapeutic-resistant SKBr-3 mammary adenocarcinoma. (▴) covalent epirubicin-(C₃-amide)-[anti-HER2/neu] immunochemotherapeutic; and (♦) anti-HER2/neu monoclonal antibody. Monolayers of mammary adenocarcinoma SKBr-3 populations were incubated with the epirubicin immunochemotherapeutic and anti-HER2/neu monoclonal immunoglobulin fraction over a 72-hour period. Cytotoxicity anti-neoplastic potency was measured as a function of MTT cell vitality stain intensity relative to matched negative reference controls.